Literature DB >> 12942685

Prospective evaluation of a D-optimal designed population pharmacokinetic study.

Bruce Green1, Stephen B Duffull.   

Abstract

Recently, methods for computing D-optimal designs for population pharmacokinetic studies have become available. However there are few publications that have prospectively evaluated the benefits of D-optimality in population or single-subject settings. This study compared a population optimal design with an empirical design for estimating the base pharmacokinetic model for enoxaparin in a stratified randomized setting. The population pharmacokinetic D-optimal design for enoxaparin was estimated using the PFIM function (MATLAB version 6.0.0.88). The optimal design was based on a one-compartment model with lognormal between subject variability and proportional residual variability and consisted of a single design with three sampling windows (0-30 min, 1.5-5 hr and 11-12 hr post-dose) for all patients. The empirical design consisted of three sample time windows per patient from a total of nine windows that collectively represented the entire dose interval. Each patient was assigned to have one blood sample taken from three different windows. Windows for blood sampling times were also provided for the optimal design. Ninety six patients were recruited into the study who were currently receiving enoxaparin therapy. Patients were randomly assigned to either the optimal or empirical sampling design, stratified for body mass index. The exact times of blood samples and doses were recorded. Analysis was undertaken using NONMEM (version 5). The empirical design supported a one compartment linear model with additive residual error, while the optimal design supported a two compartment linear model with additive residual error as did the model derived from the full data set. A posterior predictive check was performed where the models arising from the empirical and optimal designs were used to predict into the full data set. This revealed the "optimal" design derived model was superior to the empirical design model in terms of precision and was similar to the model developed from the full dataset. This study suggests optimal design techniques may be useful, even when the optimized design was based on a model that was misspecified in terms of the structural and statistical models and when the implementation of the optimal designed study deviated from the nominal design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942685     DOI: 10.1023/a:1024467714170

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  15 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Authors:  Y Merlé; M Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

Review 3.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

Authors:  M Laposata; D Green; E M Van Cott; T W Barrowcliffe; S H Goodnight; R C Sosolik
Journal:  Arch Pathol Lab Med       Date:  1998-09       Impact factor: 5.534

4.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

5.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.

Authors:  A N Teien; M Lie
Journal:  Thromb Res       Date:  1977-03       Impact factor: 3.944

6.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

7.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

8.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

9.  Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients.

Authors:  G J Yuen; G L Drusano; A Forrest; K Plaisance; E S Caplan
Journal:  Clin Pharmacol Ther       Date:  1989-10       Impact factor: 6.875

10.  A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.

Authors:  G L Drusano; A Forrest; K I Plaisance; J C Wade
Journal:  Clin Pharmacol Ther       Date:  1989-06       Impact factor: 6.875

View more
  22 in total

Review 1.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.

Authors:  Stefanie Hennig; Timothy H Waterhouse; Scott C Bell; Megan France; Claire E Wainwright; Hugh Miller; Bruce G Charles; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10-30       Impact factor: 4.335

4.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

5.  An examination of effect estimation in factorial and standardly-tailored designs.

Authors:  Heather G Allore; Terrence E Murphy
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

6.  Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.

Authors:  Michael A Barras; Stephen B Duffull; John J Atherton; Bruce Green
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

7.  Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations.

Authors:  Chihiro Hasegawa; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-05-26       Impact factor: 2.745

8.  Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study.

Authors:  Catherine M T Sherwin; Pornswan Ngamprasertwong; Senthilkumar Sadhasivam; Alexander A Vinks
Journal:  Curr Clin Pharmacol       Date:  2014-02

9.  Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.

Authors:  B Green; M Greenwood; D Saltissi; J Westhuyzen; L Kluver; J Rowell; J Atherton
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

10.  Towards optimal design of anti-malarial pharmacokinetic studies.

Authors:  Julie A Simpson; Kris M Jamsen; Ric N Price; Nicholas J White; Niklas Lindegardh; Joel Tarning; Stephen B Duffull
Journal:  Malar J       Date:  2009-08-06       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.